Faculty Profile

Dr. Thomas J. Ow, M.D.

Thomas J. Ow, M.D.

Associate Professor, Department of Otorhinolaryngology - Head & Neck Surgery

Associate Professor, Department of Pathology

Areas of Research: Head and neck cancer biology; Molecular and genetic biomarkers in head and neck squamous cell carcinoma; Head and neck skin cancer diagnosis and outcomes; Thyroid cancer diagnosis and outcomes.

Professional Interests

Dr. Ow is a Head and Neck Surgeon and Translational Researcher at Montefiore Medical Center-Albert Einstein College of Medicine.  He specializes in the surgical treatment of tumors in the head and neck region, including those that occur in the mouth, throat, larynx, neck, sinuses, salivary glands, and thyroid gland.  He also specializes in the surgical treatment of skin cancers that occur on the scalp, face, and neck. 

Dr. Ow’s research is focused on the translation of genetic and molecular determinants in head and neck squamous cell cancer into clinically useful biomarkers and therapeutic targets.  Specifically, Dr. Ow is studying factors that contribute to radiation and chemotherapy resistance in this disease, as well as genomic alterations acquired during the process of locoregional recurrence, lymph node spread, and distant metastasis.  As a translational scientist, Dr. Ow is involved in active projects studying  in vitro models of HNSCC, research utilizing patient's tumors, as well as clinical research - both retrospective studies and prospective clinical trials.  The ultimate goal of this work is to identify novel ways to improve the survival and functional outcomes among patients with HNSCC. 

Selected Publications

Ow, TJ; Sandulache, VC; Skinner, HD; Myers, JM.  Integration of cancer genomics with treatment selection:  from the genome to predictive biomarkers.  Cancer.  2013 (Accepted)

Ow, TJ; Hanna, EY; Roberts, DB; Levine NB; El-Naggar AK; Rosenthal, DI; DeMonte, F,Kupferman, ME.  Optimization of long-term outcomes for patients with esthesioneuroblastoma.  Head and Neck. Head Neck. 2013 Jun 18. doi: 10.1002/hed.23327. [Epub ahead of print]

Hamilton JD, Sandulache VC, Ahmed S, Daram SP, Ow TJ, Skinner HD, Rao A, Myers JN. Improving Imaging Diagnosis for Residual Nodal Disease after Definitive Therapy for Oropharyngeal Carcinoma: Specific Signs for CT and Best Performance of Combined Criteria.  Am J Neuroradiol. 2013 Mar 7. [Epub ahead of print]

Sandulache VC, Ow TJ, Daram SP, Hamilton J, Skinner H, Bell D, Rosenthal DI, Beadle BM, Ang KK, Kies MS, Johnson FM, El-Naggar AK, Myers JN.  Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival. Head Neck. 2012 Sep 28.

Sandulache VC, Skinner HD, Wang Y, Chen Y, Dodge CT, Ow TJ, Bankson JA, Myers JN, Lai SY.Glycolytic inhibition alters anaplastic thyroid carcinoma tumor metabolism and improves response to conventional chemotherapy and radiation.  Mol Cancer Ther. 2012 Jun;11(6):1373-80. 

Skinner, HD; Sandulache, VC; Ow, TJ; Meyn, RE; Yordy, JS; Beadle, BM; Fitzgerald, AL; Giri, U; Ang, KK; Myers, JN. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res. 2012 Jan 1;18(1):290-300. Epub 2011 Nov 16. 

Ow, TJ*; Sano, D.*; Xie, TX*; Zhao, M; Pickering, CR; Zhou, G; Sandulache, VC; Wheeler, DA; Gibbs, RA; Caulin, C; Myers, JN.  Disruptive TP53 Mutation is Associated with Aggressive Disease Characteristics in an Orthotopic Murine Model of Oral Tongue Cancer .  2011 Nov 1;17(21):6658-70.     *Co-First Authors 

Zhao, M; Sano, D; Pickering, CR;Jasser, SA; Henderson, YC; Clayman, GL; Sturgis, EM;Ow, TJ; Lotan R; Carey, TE; Sacks, PG; Grandis, JR; Sidransky, D; Nils, EH; Myers, JN.  Assembly And Initial Characterization Of A Panel Of 85 Genomically Validated Cell Lines From Diverse Head And Neck Tumor Sites. Clin Cancer Res.  2011 Dec 1;17(23):7248-7264. 

Sandulache, VC; Skinner, HD; Ow, TJ; Zhang, A; Xia, X; Luchak, JM; Wong, LJC; Pickering, CR; Zhou, G; Myers, JN.  Individualizing anti-metabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status. Cancer. 2012 Feb 1;118(3):711-21. 

Sandulache VC, Ow TJ, Pickering CR, Frederick MJ, Zhou G, Fokt I, Davis-Malesevich M, Priebe W, Myers JN. Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells.  Cancer, 2011 Jul 1;117(13):2926-38.

Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.

Montefiore Medical Center
Medical Arts Pavilion
3400 Bainbridge Avenue
MMC-MAP, Room 3304
Bronx, NY 10467

Tel: 718.920.8488
Fax: 718.405.9014

Research Information